☆ 4.6 Letter

[68Ga]Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression After Myocardial Infarction

JACC-CARDIOVASCULAR IMAGING (2015)

Journal

JACC-CARDIOVASCULAR IMAGING

Volume 8, Issue 12, Pages 1466-1468

Publisher

ELSEVIER SCIENCE INC

DOI: 10.1016/j.jcmg.2015.09.007

Keywords

-

Categories

Cardiac & Cardiovascular Systems Radiology, Nuclear Medicine & Medical Imaging

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Medicine, Research & Experimental

CXCR4 PET imaging of mantle cell lymphoma using [68Ga]Pentixafor: comparison with [18F]FDG-PET

Marius E. Mayerhoefer, Markus Raderer, Wolfgang Lamm, Verena Pichler, Sarah Pfaff, Michael Weber, Barbara Kiesewetter, Markus Hacker, Lukas Kazianka, Philipp B. Staber, Hans-Juergen Wester, Johannes Rohrbeck, Ingrid Simonitsch-Klupp, Alexander Haug

Summary: In this prospective study, [Ga-68]Pentixafor-PET showed higher sensitivity and detection rates compared to [F-18]FDG-PET in patients with mantle cell lymphoma (MCL), indicating that it may be a potential alternative for imaging in these patients. The study also found that SUVs and TBRs were significantly higher for [Ga-68]Pentixafor-PET, with the most notable difference observed in mean TBRblood values.

THERANOSTICS (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms Using 68Ga-Pentixafor PET

Andreas K. Buck, Alexander Haug, Niklas Dreher, Alessandro Lambertini, Takahiro Higuchi, Constantin Lapa, Alexander Weich, Martin G. Pomper, Hans-Juergen Wester, Anja Zehndner, Andreas Schirbel, Samuel Samnick, Marcus Hacker, Verena Pichler, Stefanie Hahner, Martin Fassnacht, Hermann Einsele, Sebastian E. Serfling, Rudolf A. Werner

Summary: In recent years, molecular imaging targeting CXCR4 has been increasingly used in various clinical settings. This study aimed to assess radiopharmaceutical uptake and image contrast to determine the clinical applications for CXCR4-directed imaging and investigate the impact of specific activity on scan contrast.

JOURNAL OF NUCLEAR MEDICINE (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Imaging CXCR4 receptors expression for staging multiple myeloma by using 68Ga-Pentixafor PET/CT: comparison with 18F-FDG PET/CT

Amit Singh Shekhawat, Baljinder Singh, Pankaj Malhotra, Ankit Watts, Rajender Basher, Harneet Kaur, Monika Hooda, Bishan D. Radotra

Summary: In this study, the diagnostic utility of Ga-68-Pentixafor PET/CT in multiple myeloma was evaluated. The results showed that it can more accurately assess CXCR4 expression and disease extent compared to F-18-FDG PET/CT, with higher TBRmax values. Additionally, Ga-68-Pentixafor PET/CT can detect extramedullary and medullary lesions. Therefore, this technique has potential importance in the diagnosis and staging of multiple myeloma.

BRITISH JOURNAL OF RADIOLOGY (2022)

Add to Collection

Article Medicine, Research & Experimental

Reduced splenic uptake on 68Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis

Sabrina Kraus, Philipp Klassen, Malte Kircher, Alexander Dierks, Stefan Habringer, Alexander Gaeble, Klaus Martin Kortuem, Niels Weinhold, Valeeza Ademaj-Kospiri, Rudolf A. Werner, Andreas Schirbel, Andreas K. Buck, Peter Herhaus, Hans-Juergen Wester, Andreas Rosenwald, Wolfgang A. Weber, Hermann Einsele, Ulrich Keller, Leo Rasche, Constantin Lapa

Summary: This study evaluates the prognostic impact of splenic CXCR4 expression in patients with multiple myeloma (MM). The findings suggest that splenic Ga-68-Pentixafor uptake is associated with disease progression, treatment history, and clinical outcome. Reduced splenic uptake is linked to unfavorable prognosis and can serve as an independent predictor of survival.

THERANOSTICS (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

CXCR4-Directed PET/CT with [68Ga]Pentixafor in Central Nervous System Lymphoma: A Comparison with [18F]FDG PET/CT

Zhenying Chen, Apeng Yang, Jiaying Zhang, Aihong Chen, Yuanqing Zhang, Chao Huang, Shaoming Chen, Shaobo Yao, Weibing Miao

Summary: The study evaluated the value of [(68) Ga]Pentixafor PET/CT for CNSL patients, showing higher accuracy and better contrast compared to [F-18]FDG PET/CT. [(68) Ga]Pentixafor PET/CT detected more lesions and had a higher T/N ratio, making it a promising agent for lesion detection in CNSL patients.

MOLECULAR IMAGING AND BIOLOGY (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

[68Ga]-Pentixafor PET/CT imaging of lymphoproliferative malignancies

Serkan Kuyumcu, Murat Yilmaz Kiran, Evsen Apaydin Arikan, Gulcin Yegen, Yasemin Sanli

Summary: This report evaluates the PET/CT uptake patterns of patients with lymphoproliferative malignancies, finding different uptake characteristics in different subtypes of lymphomas and CLL patients. However, further studies are needed to determine the potential complementary role of [Ga-68]-Pentixafor PET/CT in personalized diagnostic concepts.

CLINICAL AND TRANSLATIONAL IMAGING (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Chemokine Receptor 4-Targeted 68Ga-Pentixafor PET/CT in Response Assessment of Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma Comparison to 18F-FDG PET/CT

Qingqing Pan, Xinxin Cao, Yaping Luo, Jian Li, Fang Li

Summary: Ga-68-pentixafor PET/CT outperforms F-18-FDG PET/CT in response assessment of WM/LPL, showing different tumor responses and detecting disease progression more effectively.

CLINICAL NUCLEAR MEDICINE (2021)

Add to Collection

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

Burkitt Lymphoma/Leukemia Presented on 68Ga-Pentixafor and 18F-FDG PET/CT

Zhenying Chen, Qianqian Xue, Chao Huang, Shaobo Yao, Weibing Miao

Summary: This study highlights the potential role of Ga-68-Pentixafor PET/CT in diagnosing and treating Burkitt lymphoma, and suggests further research directions.

CLINICAL NUCLEAR MEDICINE (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Functional nodules in primary aldosteronism: identification of CXCR4 expression with 68Ga-pentixafor PET/CT

Yinjie Gao, Jie Ding, Yunying Cui, Tianyi Li, Hao Sun, Dachun Zhao, Yushi Zhang, Li Huo, Anli Tong

Summary: Ga-68-pentixafor PET/CT shows high sensitivity and specificity in the diagnosis of functional nodules in primary aldosteronism. It performs better in detecting nodules with a diameter greater than 1 cm.

EUROPEAN RADIOLOGY (2023)

Add to Collection

Review Oncology

The Role of [68Ga]Ga-Pentixafor PET/CT or PET/MRI in Lymphoma: A Systematic Review

Domenico Albano, Francesco Dondi, Francesco Bertagna, Giorgio Treglia

Summary: Preliminary evidence suggests that [Ga-68]Ga-Pentixafor PET/CT or PET/MRI may have a useful impact in lymphoma, particularly in FDG-not-avid variants. This systematic review aimed to analyze published data on the role of [Ga-68]Ga-Pentixafor PET/CT or PET/MRI in lymphoma, with a focus on different lymphoma variants and clinical applications. The findings indicate that [Ga-68]Ga-Pentixafor PET can be considered a valuable imaging method for staging and evaluating treatment response in multiple lymphomas, including MZL, CNSL, and LPL. There is also evidence to suggest that [Ga-68]Ga-Pentixafor PET may have better diagnostic performance than [F-18]FDG PET in assessing lymphomas.

CANCERS (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Usefulness of 68Ga-Pentixafor PET/CT on Diagnosis and Management of Cushing Syndrome

Jie Ding, Anli Tong, Marcus Hacker, Ming Feng, Li Huo, Xiang Li

Summary: This study investigated the performance of Ga-68-pentixafor in different subtypes of Cushing syndrome, demonstrating its potential in the differential diagnosis of both ACTH-independent and ACTH-dependent CS. The high sensitivity and specificity of Ga-68-pentixafor PET/CT for diagnosing cortisol-producing adenoma and differentiating ACTH-PA were highlighted.

CLINICAL NUCLEAR MEDICINE (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [68Ga]Ga-PentixaFor PET/CT

Sebastian E. Serfling, Constantin Lapa, Niklas Dreher, Philipp E. Hartrampf, Steven P. Rowe, Takahiro Higuchi, Andreas Schirbel, Alexander Weich, Stefanie Hahner, Martin Fassnacht, Andreas K. Buck, Rudolf A. Werner

Summary: This study aimed to determine the potential correlation between tumor burden and radiotracer accumulation in normal organs in patients with solid tumors imaged with CXCR4-directed PET/CT. The results showed no significant correlation between radiotracer uptake in tumor lesions and normal organs.

MOLECULAR IMAGING AND BIOLOGY (2022)

Add to Collection

Editorial Material Medicine, General & Internal

68Ga-Pentixafor PET/CT May Fail to Detect Recurrent Multiple Myeloma with Extramedullary Disease

Qingqing Pan, Yaping Luo, Xinxin Cao, Jian Li, Fang Li

Summary: Two patients with a history of multiple myeloma had a recurrence of the disease. F-18-FDG PET/CT showed prominent extramedullary disease and multi-foci in the bone marrow with increased FDG uptake. However, Ga-68-Pentixafor PET/CT revealed significantly lower tracer uptake in all myeloma lesions compared to F-18-FDG PET. This false-negative result in assessing multiple myeloma with extramedullary disease may indicate a potential limitation of Ga-68-Pentixafor.

DIAGNOSTICS (2023)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

CXCR4-directed PET/CT with [68 Ga]Ga-pentixafor in solid tumors-a comprehensive analysis of imaging findings and comparison with histopathology

Niklas Dreher, Stefanie Hahner, Carmina T. Fuss, Wiebke Schloetelburg, Philipp E. Hartrampf, Sebastian E. Serfling, Andreas Schirbel, Samuel Samnick, Takahiro Higuchi, Alexander Weich, Constantin Lapa, Andreas Rosenwald, Andreas K. Buck, Stefan Kircher, Rudolf A. Werner

Summary: This study aimed to characterize the in-vivo CXCR4 expression in patients with solid tumors and compare it to ex-vivo findings. The results showed that a substantial proportion of prevalent solid tumors demonstrated increased and uniform [(68)Ga]Ga-pentixafor uptake, indicating high image contrast. Additionally, a fraction of patients with [(68)Ga]Ga-pentixafor-positive tumor burden were potentially suitable for CXCR4-directed therapy.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2023)

Add to Collection

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

68Ga-DOTATATE PET/CT Imaging of Refractory Pituitary Macroadenoma Invading the Orbit

Noah Lybik, Daniel J. Wale, Ka Kit Wong, Eric Liao, Benjamin L. Viglianti

Summary: Somatostatin receptor imaging, commonly used in neuroendocrine oncology, may have diagnostic utility in various tumors beyond gastroenteropancreatic neuroendocrine neoplasms. In challenging cases, theranostic principles utilizing somatostatin receptor-based therapy could offer potential treatment options.

CLINICAL NUCLEAR MEDICINE (2021)

Add to Collection

Article Oncology

Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma

Alexander M. Leipold, Rudolf A. Werner, Johannes Duell, Pius Jung, Mara John, Emilia Stanojkovska, Xiang Zhou, Hannah Hornburger, Anna Ruckdeschel, Oliver Dietrich, Fabian Imdahl, Tobias Krammer, Stefan Knop, Andreas Rosenwald, Andreas Buck, Leif Erik Sander, Hermann Einsele, K. Martin Kortuem, Antoine-Emmanuel Saliba, Leo Rasche

Summary: This article presents a case study on pulmonary flare-up after Ide-cel therapy and identifies a Th17.1 driven autoimmune mechanism as the cause. The study also reveals transcriptomic similarities between post CAR T pulmonary lesions and sarcoidosis. Furthermore, a noninvasive PET diagnostic approach using multiple tracers is explored, which helps discriminate between immune-mediated changes and true relapse after CAR T-cell treatment.

LEUKEMIA (2023)

Add to Collection

Article Endocrinology & Metabolism

Lack of repeatability of radiomic features derived from PET scans: Results from a 18F-DCFPyL test-retest cohort

Rudolf A. Werner, Bilel Habacha, Susanne Luetje, Lena Bundschuh, Alekandser Kosmala, Markus Essler, Thorsten Derlin, Takahiro Higuchi, Constantin Lapa, Andreas K. Buck, Kenneth J. Pienta, Martin A. Lodge, Mario A. Eisenberger, Mark C. Markowski, Martin G. Pomper, Michael A. Gorin, Eric C. Frey, Steven P. Rowe, Ralph A. Bundschuh

Summary: This study aimed to assess the repeatability of radiomic features on PET in a test-retest setting. By analyzing the data of 21 patients with metastatic prostate cancer who underwent two F-18-DCFPyL PET scans, it was found that entropy and homogeneity had good repeatability and could be used as image biomarkers in future clinical trials.

PROSTATE (2023)

Add to Collection

Article Oncology

Predicting Microenvironment in CXCR4-and FAP-Positive Solid Tumors-A Pan-Cancer Machine Learning Workflow for Theranostic Target Structures

Andre Marquardt, Philipp Hartrampf, Philip Kollmannsberger, Antonio G. Solimando, Svenja Meierjohann, Hubert Kuebler, Ralf Bargou, Bastian Schilling, Sebastian E. Serfling, Andreas Buck, Rudolf A. Werner, Constantin Lapa, Markus Krebs

Summary: Imaging based on positron emission tomography (PET) is crucial in modern cancer care. C-X-C Motif Chemokine Receptor 4 (CXCR4) and Fibroblast Activation Protein Alpha (FAP) have emerged as clinically significant PET targets. Using machine learning, the study found that high levels of CXCR4 in solid tumors were associated with immune cell infiltration, while FAP-positive tumors were characterized by high levels of tumor vessels. This approach has the potential to identify vulnerabilities in tumors without invasive procedures.

CANCERS (2023)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Somatostatin Receptor-Directed PET/CT for Therapeutic Decision-Making and Disease Control in Patients Affected With Small Cell Lung Cancer

Sebastian E. Serfling, Philipp E. Hartrampf, Yingjun Zhi, Takahiro Higuchi, Aleksander Kosmala, Julia Serfling, Andreas Schirbel, Anna Hoerning, Andreas K. Buck, Alexander Weich, Rudolf A. Werner

Summary: A study found that SSTR-targeted PET/CT can lead to changes in therapeutic management in patients with small cell lung cancer (SCLC), resulting in disease control and prolonged survival.

CLINICAL NUCLEAR MEDICINE (2023)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Interobserver Agreement Rates on C-X-C Motif Chemokine Receptor 4-Directed Molecular Imaging and Therapy

Philipp E. Hartrampf, Aleksander Kosmala, Sebastian E. Serfling, Lena Bundschuh, Takahiro Higuchi, Constantin Lapa, Steven P. Rowe, Yohji Matsusaka, Alexander Weich, Andreas K. Buck, Ralph A. Bundschuh, Rudolf A. Werner

Summary: In this study, we evaluated the agreement rates between observers in patients scanned with CXCR4-targeted PET/CT, including the percentage of patients eligible for CXCR4-targeted RLT based on the scan results. Fair to excellent agreement rates were observed for both visual and quantitative assessments, indicating the potential widespread adoption of [Ga-68]pentixafor in the clinic.

CLINICAL NUCLEAR MEDICINE (2023)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T

Philipp E. Hartrampf, Thomas Huettmann, Anna Katharina Seitz, Hubert Kuebler, Sebastian E. Serfling, Wiebke Schloetelburg, Kerstin Michalski, Steven P. Rowe, Martin G. Pomper, Andreas K. Buck, Uta Eberlein, Rudolf A. Werner

Summary: A lower SUVmean derived from [F-18]PSMA-1007, higher CRP, lower hemoglobin, and the presence of liver metastases are associated with reduced overall survival in patients undergoing RLT. An early risk factor model also demonstrated that an increasing number of these factors is linked to worse outcome, emphasizing the importance of clinical and imaging parameters for adequate risk stratification.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2023)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Molecular imaging of arterial fibroblast activation protein: association with calcified plaque burden and cardiovascular risk factors

Aleksander Kosmala, Sebastian E. Serfling, Kerstin Michalski, Thomas Lindner, Andreas Schirbel, Takahiro Higuchi, Philipp E. Hartrampf, Thorsten Derlin, Andreas K. Buck, Alexander Weich, Rudolf A. Werner

Summary: The purpose of this study was to assess the prevalence, distribution, and intensity of in-vivo arterial wall fibroblast activation protein (FAP) uptake, and its correlation with calcified plaque burden, cardiovascular risk factors (CVRFs), and FAP-avid tumor burden. The study found a significant correlation between FAP uptake and calcified plaque burden, but inconsistent correlation with cardiovascular risk factors.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2023)

Add to Collection

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

Sarcoidosis mimicking nodal manifestations of marginal zone lymphoma

Johanna S. S. Enke, Nic G. G. Reitsam, Tina Schaller, Rainer Claus, Constantin Lapa, Alexander Dierks

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2023)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand Therapy

Philipp E. Hartrampf, Patrick W. Mihatsch, Anna Katharina Seitz, Lilja B. Solnes, Steven P. Rowe, Martin G. Pomper, Hubert Kuebler, Thorsten A. Bley, Andreas K. Buck, Rudolf A. Werner

Summary: Being overweight is associated with prolonged overall survival, while sarcopenia is associated with shorter overall survival in patients with prostate cancer scheduled for systemic treatment. The study investigated the predictive value of fat-related and body composition parameters in patients undergoing PSMA-directed RLT.

JOURNAL OF NUCLEAR MEDICINE (2023)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Theranostics in Hematooncology

Andreas K. Buck, Sebastian E. Serfling, Sabrina Kraus, Samuel Samnick, Niklas Dreher, Takahiro Higuchi, Leo Rasche, Hermann Einsele, Rudolf A. Werner

Summary: This article discusses the novel and established radiopharmaceuticals used for treating hematologic neoplasms, the use of small molecules specifically binding to C-X-C motif chemokine receptor 4 as theranostic agents, and the advantages and disadvantages of lymphoma treatment using radioimmunoconjugates.

JOURNAL OF NUCLEAR MEDICINE (2023)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

CXCR4-Directed Imaging and Endoradiotherapy in Desmoplastic Small Round Cell Tumors

Ingo Hartlapp, Philipp E. Hartrampf, Sebastian E. Serfling, Vanessa Wild, Alexander Weich, Leo Rasche, Sabine Roth, Andreas Rosenwald, Patrick W. Mihatsch, Anne Hendricks, Armin Wiegering, Verena Wiegering, Heribert Haenscheid, Andreas Schirbel, Rudolf A. Werner, Andreas K. Buck, Hans-Juergen Wester, Hermann Einsele, Volker Kunzmann, Constantin Lapa, K. Martin Kortuem

Summary: This study validates CXCR4 as a diagnostic biomarker and a promising target for endoradiotherapy in DSRCT. Additionally, it provides initial evidence of the safety and clinical efficacy of endoradiotherapy.

JOURNAL OF NUCLEAR MEDICINE (2023)

Add to Collection

Review Radiology, Nuclear Medicine & Medical Imaging

Role of Functional SPECT and PET in Renal Emergencies

Takahiro Higuchi, Philipp E. Hartrampf, Andreas K. Buck, Martin G. Pomper, Steven P. Rowe, Sebastian E. Serfling, Rudolf A. Werner

Summary: Renal scintigraphy is a crucial component of nuclear medicine and is widely used in (peri-)acute care. It is employed for diagnosing acute obstructions, functional issues, infections, and traumas related to the kidneys.

SEMINARS IN NUCLEAR MEDICINE (2023)

Add to Collection

Article Pharmacology & Pharmacy

Rationalizing the Binding Modes of PET Radiotracers Targeting the Norepinephrine Transporter

Anna Tutov, Xinyu Chen, Rudolf A. Werner, Saskia Muehlig, Thomas Zimmermann, Naoko Nose, Kazuhiro Koshino, Constantin Lapa, Michael Decker, Takahiro Higuchi

Summary: A new PET radiotracer, F-18-AF78, has shown great potential for clinical application. It belongs to a new generation of phenethylguanidine-based norepinephrine transporter (NET)-targeting radiotracers. Systematic investigations of the structure-activity relationships (SARs) of NET-targeting radiotracers have rarely been performed.

PHARMACEUTICS (2023)

Add to Collection

Article Oncology

In-Vivo Somatostatin-Receptor Expression in Small Cell Lung Cancer as a Prognostic Image Biomarker and Therapeutic Target

Feyza Sen, Gabriel T. Sheikh, Johannes von Hinten, Andreas Schindele, Malte Kircher, Alexander Dierks, Christian H. Pfob, Sebastian E. Serfling, Andreas K. Buck, Theo Pelzer, Takahiro Higuchi, Alexander Weich, Ralph A. Bundschuh, Rudolf A. Werner, Constantin Lapa

Summary: Despite the availability of novel targeted treatment options, small cell lung cancer (SCLC) still has a poor prognosis. This study aimed to evaluate the prognostic value of somatostatin receptor (SSTR) expression assessed by positron emission tomography (PET) and investigate the efficacy of SSTR-targeted radionuclide therapy (PRRT). The results showed that SSTR-targeted PET is not a prognostic tool for outcome in SCLC patients, but it can be an important tool for treatment decision. PRRT may be a promising treatment option for some patients with SCLC as a second or third line treatment.

CANCERS (2023)

Add to Collection

Article Urology & Nephrology

Image acquisition and interpretation of 18F-DCFPyL (piflufolastat F 18) PET/CT: How we do it

Steven P. Rowe, Andrew F. Voter, Rudolf A. Werner, Katherine A. Zukotynski, Martin G. Pomper, Michael A. Gorin, Lilja B. Solnes

Summary: Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) has become the standard-of-care for imaging of men with prostate cancer. The approval of 18F-DCFPyL, a radiofluorinated small molecule with high affinity for PSMA, was based on two key registration trials, OSPREY and CONDOR. This manuscript provides a review of the trials, discusses the clinical acquisition protocol for 18F-DCFPyL PET scanning, presents important information on pearls and pitfalls, introduces the PSMA reporting and data system interpretive framework, and suggests future research directions.

CANADIAN JOURNAL OF UROLOGY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.